

# 144 - Reduction schedules

## Reduction schedules

470 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 11. Horowitz M, et al. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. Oxford: Wiley- Blackwell; 2024. 12. Horowitz MA, et al. Addiction and physical dependence are not the same thing. *Lancet Psychiatry* 2023; 10:e23. 13. Guina J, et al. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. *J Clin Med* 2018; 7:17. 14. Gutierrez MA, et al. Paradoxical reactions to benzodiazepines. *Am J Nurs* 2001; 101:34-40. 15. Crowe SF, et al. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. *Arch Clin Neuropsychol* 2017; 33:901-911. 16. Brandt J, et al. Benzodiazepines and z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. *Drugs R D* 2017; 17:493-507. 17. Donnelly K, et al. Benzodiazepines, z-drugs and the risk of hip fracture: a systematic review and meta-analysis. *PLoS One* 2017; 12:e0174730. 18. Golombok S, et al. Cognitive impairment in long-term benzodiazepine users. *Psychol Med* 1988; 18:365-374. 19. Finkle WD, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. *J Am Geriatr Soc* 2011; 59:1883-1890. 20. Molero Y, et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. *BMJ* 2019; 365:l2147. 21. Schweizer E, et al. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. *Arch Gen Psychiatry* 1990; 47:908-915. 22. Schweizer E, et al. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. *Acta Psychiatr Scand* 1998; 98 Suppl 393:95-101. 23. Uhlenhuth EH, et al. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. *J Clin Psychopharmacol* 1999; 19:23S-29S. 24. Ashton H. The diagnosis and management of benzodiazepine dependence. *Curr Opin Psychiatry* 2005; 18:249-255. 25. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. *Br J Addict* 1987; 82:665-671. 26. US Food and Drug Administration. FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class: includes potential for abuse, addiction, and other serious risks 2020 (last accessed July 2024); <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class#:~:text=FDA>. 27. Ashton H. Protracted withdrawal from benzodiazepines: the post-withdrawal syndrome. *Psychiatr Ann* 1995; 1:174-179. 28. Ritvo AD, et al. Long-term consequences of benzodiazepine-induced neurological dysfunction: a survey. *PLoS One* 2023; 18:e0285584. 29. Soyka M. Treatment of benzodiazepine dependence. *N Engl J Med* 2017; 376:1147-1157. 30. Petursson H. The benzodiazepine withdrawal syndrome. *Addiction* 1994; 89:1455-1459. 31. Tannenbaum C, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults

through direct patient education: the EMPOWER cluster randomized trial. *JAMA Intern Med* 2014; 174:890–898. 32. Guy. A, et al. *Guidance for Psychological Therapists: Enabling Conversations with Clients Taking or Withdrawing from Prescribed Psychiatric Drugs*. London: APPG for Prescribed Drug Dependence; 2019. 33. Parr JM, et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. *Addiction* 2009; 104:13–24. 34. Denis C, et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. *Cochrane Database Syst Rev* 2006; (3):CD005194. 35. Ashton H. *Benzodiazepines: How They Work and How to Withdraw*. 2002 (last accessed February 2025); <http://www.benzo.org.uk/manual/bzcha01.htm>. 36. Ashton H. Benzodiazepine dependence. Adverse syndromes and psychiatric drugs. In: *Adverse Syndromes and Psychiatric Drugs: A Clinical Guide*. Oxford: Oxford University Press; 2004:239–260. 37. Brouillet E, et al. In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. *Brain Res* 1991; 557:167–176. 38. Inner Compass Initiative Inc. *The Withdrawal Project*. 2024; <https://withdrawal.theinnercompass.org>. 39. Pollmann AS, et al. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. *BMC Pharmacol Toxicol* 2015; 16:19. 40. Kales A, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. *Clin Pharmacol Ther* 1991; 49:468–476.

---

Revision #1

Created 2026-01-04 20:15:15 UTC by Omar Ayman

Updated 2026-01-04 20:15:15 UTC by Omar Ayman